Business Context and Reporting Period
This Form 8-K filing by Enanta Pharmaceuticals, Inc. covers the period ending March 25, 2013. The report details corporate governance amendments and the formalization of the company's capital structure immediately following its Initial Public Offering (IPO), which closed on March 26, 2013.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate charter amendments and does not contain financial performance data.
Material Changes
- Capital Structure: All outstanding series of convertible preferred stock automatically converted into common stock upon the IPO closing.
- Authorized Shares: Following the retirement of preferred stock, the total authorized capital stock was reduced to 104,999,989 shares, with authorized preferred stock reduced to 4,999,989 shares.
- Governance Documents: The company filed a Restated Certificate of Incorporation and Amended and Restated Bylaws effective as of the IPO.
Outlook, Risks, and Corporate Provisions
The new Restated Certificate of Incorporation and Bylaws establish several key governance provisions:
- Staggered Board: The board of directors is divided into three classes (I, II, and III) with staggered three-year terms.
- Director Removal: Directors may be removed only for cause, requiring an affirmative vote of at least 66 2/3% of stockholder votes.
- Liability Limitations: Director and officer liability is limited to the fullest extent permitted under Delaware General Corporation Law.
- Stockholder Actions: The right of stockholders to act by written consent without a meeting has been eliminated.
- Bylaw Amendments: Bylaws may be amended by a majority vote of the board or 66 2/3% of stockholder votes.
- Board Vacancies: Vacancies, including those from board enlargement, may be filled only by a majority vote of directors then in office.
Key Facts for Investor Verification
- Verify the final share count and capitalization table post-IPO conversion.
- Review the full text of the Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for specific anti-takeover implications.
- Confirm the effective date of the staggered board terms relative to the first annual meeting.
- Check subsequent filings for the actual proceeds and use of funds from the March 26, 2013 IPO.